HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Immunotherapy 101 for Multiple Myeloma Patients
Immunotherapy 101 for Multiple Myeloma Patients image
Immunotherapy (CAR T, Bispecifics and more) Treatment Chapter
event Nov 15, 2022 / 01:00PM - 02:00PM EST

Event Description

Myeloma expert Dr. Malin Hultcrantz is back due to popular demand. This time she shares with us a crash course in Immunotherapy. What makes immunotherapy different? Will it "take over" chemotherapy? Is it available for newly diagnosed patients? Learn answers to these questions and come with your own. We're looking forward to it!


Schedule & Agenda

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Malin Hultcrantz.

The panelist Malin Hultcrantz, MD, PhD
Malin Hultcrantz, MD, PhD

Dr. Malin Hultcrantz shares with us a crash course in Immunotherapy.


Questions and Answers
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Malin Hultcrantz, MD, PhD
Malin Hultcrantz, MD, PhD

Malin Hultcrantz, MD, PhD, is a board-certified hematologist who specializes in the treatment of multiple myeloma and related plasma cell disorders including the precursor disorders monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma at the Memorial Sloan Kettering Cancer Center. She is focused on further optimizing treatment strategies for people with multiple myeloma, and offers a variety of modern treatments including clinic trials and novel immunotherapies. She is also working on measures to continue to improve patients’ quality of life while receiving treatment for multiple myeloma. Additionally, she has a particular interest in studying mechanisms and markers of progression from precursor disease to multiple myeloma. As part of this effort, she is working with her colleagues to develop targeted genomic tests for disease characterization and measurement of minimal residual disease. Better understanding of disease biology allows for better risk stratification and personalized treatment including early treatment for patients with high-risk precursor disease. In 2015, Dr. Hultcrantz received the Research Fellow Award, Multiple Myeloma Research Foundation and the International Postdoc Award, Swedish Research Council. Dr. Hultcrantz is fluent in Swedish and English.

Read Bio
The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube